bioAffinity Technologies, Inc. ((BIAF)) just unveiled an update.
bioAffinity Technologies, Inc. reports a successful year in 2024, with significant sales and activity growth through its lung cancer detection product, CyPath Lung. The company plans to expand its market presence through 2025, leveraging growth in the U.S. healthcare system and focusing on key regions and markets, including the VA and military sectors, to further increase the accessibility and acceptance of its test to increase.
More about bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. is active in the medical diagnostics industry and focuses on the early detection of lung cancer through its non-invasive test, CyPath Lung. The company aims to address the critical need for early cancer detection and holds patents in the US, European Union and Asia, with a significant market presence in these regions.
YTD Price Performance: -19.73%
Average trading volume: 140,230
Technical sentiment consensus rating: Buy
View more data on the BIAF stock at TipRanks’ Stock Analysis Page.
